Recon: Boehringer slated to cap asthma inhaler costs at $35 a month; Novo surges on early-stage obesity drug data

• Biden to propose expanding Medicare drug price negotiation in State of the Union (STAT)
• Drugmakers gear up for joint IRA arguments as PhRMA appeals Texas verdict (Endpoints)
• Senate panel advances bill to ban some Chinese biotechs, with Sen. Paul taking up industry’s cause (STAT)
• A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data (STAT)
• Boehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35 (STAT)
• FDA sees success in model-informed drug development pilot (Endpoints)
• Valisure pressures FDA to recall acne treatments after finding carcinogen (Endpoints)
• How to Run DMC? It’s Tricky – FDA’s New Draft Guidance Provides Updated Recommendations on How to Best Use Data Monitoring Committees in Clinical Trials (FDA Law Blog)
• Lilly finds bacteria, other impurities in Mounjaro, Zepbound knockoffs (Reuters)
• Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows (Reuters)

• Novo Nordisk’s obesity pill bests Wegovy in early trial (STAT) (Reuters) (Endpoints)
• WTO proposal for Covid diagnostics and therapeutics waiver is abandoned (STAT)
• WHO flags increasing resistance to GSK's HIV med Tivicay in some countries (Fierce Pharma)
• AstraZeneca pledges £650M in UK investments to boost vaccine capabilities, expand near HQ (Fierce Pharma)
• Generics Group Urges Action On Licensing Delays As MHRA Unveils Guidance For Established Products (Pink Sheet)
• Cut In Data Protection Looms Large As EU Vote On Pharma Revision Nears (Pink Sheet) (Pink Sheet)

• UCB ups the ante with CDMO Samsung Biologics, signing $353M deal (Fierce Pharma)
• Merck KGaA exits BTK inhibitor race, will focus on ‘external innovation’ (Endpoints)
• GSK declares second PhIII win for Blenrep combo in bid to revive drug (Endpoints)
• Sun Pharma re-enlists popular ‘Pimple Popper’ doctor for acne brand TV campaign (Endpoints)
• Tarsus’ eye drops interrupt an animated mite 'party’ in first DTC ad for Xdemvy (Endpoints)
• Early-stage oncology startup Boundless Bio files for IPO (Endpoints)
• Sumitomo to lay off about 400 employees, reshuffle execs in North America as sales disappoints (Endpoints)
• Evonik, looking to cut costs, shrinks workforce by 2,000 in structural overhaul (Fierce Pharma)
• Growing Almac boosts capacity for manufacturing peptides and packaging commercial products (Fierce Pharma)
• Argonaut's journey continues with $45M in new financing for facility expansion (Fierce Pharma)

• Oracle Health chair says Cerner isn’t competing with Epic (STAT)
• Health tech investors outline investment priorities in AI (Endpoints)
• Vicarious presses forward with soft tissue robot despite struggles (MedTech Dive)
• Dexcom receives FDA clearance for first OTC glucose sensor (MedTech Dive)
• Smiths Medical recalls nearly 86,000 syringe pumps over software problem (MedTech Dive)

• Former medical device CEO who sold dummy, plastic parts convicted of fraud (STAT)
• Advisory Committees: US FDA Standardizing Decisions On When To Vet Applications (Pink Sheet)
• FDA finds lead contamination in certain ground cinnamon products, asks manufacturers to voluntarily recall items (The Hill)